MADRID — rimonabant canada, the novel cannabinoid type 1 receptor-blocking drug that has been gaining considerable attention for its ability to induce weight loss, improve glucose metabolism, raise HDL cholesterol and lower triglycerides, also appears to lead to small but meaningful reductions in blood pressure in hypertensive obese patients.

SAN DIEGO — The investigational drug rimonabant canada produces highly significant cardiovascular and metabolic benefit in patients with type 2 diabetes, Andre Scheen, M.D., reported at the annual scientific sessions of the American Diabetes Association.

Millions of Americans take popular drugs to lose weight, but the long-term risks and benefits of these medications aren’t known, two Canadian researchers contend. Drs. Raj Padwal and Sumit Majumdar, of the University of Alberta, said long-term studies are needed to determine whether losing weight on drugs such as sibutramine (Meridia), orlistat (Xenical) and rimonabant canada (Acomplia) actually reduces the risks of heart attack, stroke and diabetes associated with being overweight or obese.

By Rebecca Jenkins LANCET Overweight and obese patients with inadequately controlled type 2 diabetes benefit by adding a weight-loss drug that blocks pleasure centres in the brain, a study suggests. canada Rimonabant (Acomplia), a selective cannabinoid-1 receptor blocker, significantly reduced weight and HbA1c levels in overweight and obese patients with type 2 diabetes, inadequately controlled with metformin or sulphonylureas.

Americans’ poor diets and inactivity are making diabetes the drug industry’s next sales bonanza. Jack S. Friedman developed diabetes when he was only 32 years old. Twenty-two years later the computer engineer weighs 265 pounds and takes insulin and nine other drugs to treat his diabetes, obesity and cholesterol.